If you have chronic rhinosinusitis with nasal polyp or allergies and would like to support our research, our highly skilled team is looking forward to talking to you!
Ongoing studies:
EpiBar: Treatment with the licensed drug dupilumab (Dupixent) for treatment of nasal polyps to investigate the role on epithelial barrier function, nasal sampling at baseline and after 3 and 6 months.
Allergy & Age: Study to investigate immune response to allergen provocation in patients with current or former respiratory allergy aged 60+We are happy to provide you with further information on our studies.
Tezebarrier: Treatment with the licensed drug tezepelumab (Tezspire) for treatment of asthma with and without nasal polyps (collaboration pulmonology) to investigate the role on epithelial barrier function in nose and lung